An update on the safety and efficacy of topical retinoids

Cutis

Volumn 75, Issue 2 SUPPL., 2005, Pages 14-24

  Phillips, Tania J ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ALITRETINOIN; BENZOYL PEROXIDE; BEXAROTENE; GLYCOLIC ACID; HYDROQUINONE; IMIQUIMOD; MINOXIDIL; PETROLATUM; RETIN A MICRO; RETINOIC ACID; RETINOID; RETINOL; SALICYLIC ACID; TAZAROTENE;

ACNE; ACTINIC KERATOSIS; ALOPECIA; ANTIINFLAMMATORY ACTIVITY; BASAL CELL CARCINOMA; BIRTH DEFECT; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG USE; DRY SKIN; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; HUMAN; KAPOSI SARCOMA; LOW LEVEL LASER THERAPY; META ANALYSIS; MOLECULAR STABILITY; NONHUMAN; PREGNANCY; PRURITUS; RADIATION INJURY; REVIEW; RISK ASSESSMENT; SKIN ABRASION; SKIN BURNING SENSATION; SKIN DISEASE; SKIN INJURY; SKIN IRRITATION; SKIN MANIFESTATION; SUN EXPOSURE; TEMPERATURE; TREATMENT OUTCOME; WOUND HEALING;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ADULT; AGE FACTORS; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PREGNANCY; RETINOIDS; RISK ASSESSMENT; SKIN AGING; TREATMENT OUTCOME; WOUND HEALING;

EID: 14744275341     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol. 2003;4:473-492.
2. Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet. 1993;341:1181-1182.
3. Nyirady J, Nighland M. Assessment of the cumulative irritation potential of six topical retinoids. Poster presented at: 61st Annual Meeting of the American Academy of Dermatology; March 21-26, 2003; San Francisco, Calif. P106.
4. Nyirady J, Grossman RM, Nighland M, et al. A comparative trial of two retinoids commonly used in the treatment of acne vulgaris. J Dermatolog Treat. 2001;12:149-157.
5. Greenspan A, Loesche C, Vendetti N, et al. Cumulative irritation comparison of adapalene gel and solution with 2 tazarotene gels and 3 tretinoin formulations. Cutis. 2003;72:76-81.
6. Cunliffe WJ, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a metaanalysis of five randomized trials. Br J Dermatol. 1998;139:48-56.
7. Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol. 1996;34:482-485.
8. Verschoore M, Langner A, Wolska H, et al. Efficacy and safety of CD 271 alcoholic gels in the topical treatment of acne vulgaris. Br J Dermatol. 1991;124:368-371.
9. Alirezai M, Meynadier J, Jablonska S, et al. Comparative study of the efficacy and tolerability of 0.1 and 0.03 p.100 adapalene gel and 0.025 p.100 tretinoin gel in the treatment of acne. Ann Dermatol Venereol. 1996;123:165-170.
10. Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. J Am Acad Dermatol. 1997;36(6 Pt 2):S126-S134.
11. Ellis CN, Millikan LE, Smith EB, et al. Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in the topical treatment of acne vulgaris. Br J Dermatol. 1998;139(suppl 52):41-47.
12. Grosshans E, Marks R, Mascaro JM, et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol. 1998;139(suppl 52):26-33.
13. Martin B, Meunier C, Montels D, et al. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol. 1998;139(suppl 52):8-11.
14. Hecker D, Worsley J, Yueh G, et al. Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol. 1999;41:927-930.
15. Kang S, Bergfeld W, Gottlieb AB, et al. Safety and efficacy o long-term use of tretinoin emollient cream 0.05% for the treatment of photodamaged facial skin: review of a clinical trial. Poster presented at: 61st Annual Meeting of the American Academy of Dermatology; March 21-26, 2003; San Francisco, Calif. P100.
16. Kang S, Goldfarb MT, Weiss JS, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. J Am Acad Dermatol. 2003;49:83-90.
17. Kang S, Leyden JJ, Lowe NJ, et al. Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel, comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks. Arch Dermatol. 2001;137:1597-1604.
18. Phillips TJ, Gottlieb AB, Leyden JJ, et al. Efficacy of 0.1% tazarotene cream for the treatment of photodamage. Arch Dermatol. 2002;138:1486-1493.
19. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis. 1999;63:349-354.
20. Leyden J, Lowe N, Kakita L, et al. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis. 2001;67(suppl 6):10-16.
21. Leyden JJ, Tanghetti EA, Miller B, et al. Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1% microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis. 2002;69(suppl 2):12-19.
22. 2 laser resurfacing. Plast Reconstr Surg. 1999;104:2229-2235.
23. Mandy SH. Tretinoin in the preoperative and postoperative management of dermabrasion. J Am Acad Dermatol. 1986;16:878-879, 888-889.
24. Hevia O, Nemeth AJ, Taylor JR. Tretinoin accelerates healing after trichloroacetic acid chemical peel. Arch Dermatol. 1991;127:678-682.
25. Popp C, Kligman AM, Stoudemayer TJ. Pretreatment of photoaged forearm skin with topical tretinoin accelerates healing of full-thickness wounds. Br J Dermatol. 1995;132:46-53.
26. Paquette D, Badiavas E, Falanga V. Short-contact topical tretinoin therapy to stimulate granulation tissue in chronic wounds. J Am Acad Dermatol. 2001;45:382-386.
27. Zachariae H. Delayed wound healing and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment. Br J Dermatol. 1988;118:703-706.
28. Otley CC, Gayner SM, Ahmed I, et al. Preoperative and postoperative topical tretinoin on high-tension excisional wounds and full-thickness skin grafts in a porcine model: a pilot study. Dermatol Surg. 1999;25:716-721.
29. 2 laser resurfacing. Dermatol Surg. 1999;25:15-17.
30. Solis RR, Diven DG, Colome-Grimmer MI, et al. Experimental nonsurgical tattoo removal in a guinea pig model with topical imiquimod and tretinoin. Dermatol Surg. 2002;28:83-86.
31. Bazzano GS, Terezakis N, Galen W. Topical tretinoin for hair growth promotion. J Am Acad Dermatol. 1986;15:880-883, 890-893.
32. Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma [letter]. N Engl J Med. 1999;341:1767-1768.
33. Duvic M, Friedman-Kien AE, Looney DJ, et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials. Arch Dermatol. 2000;136:1461-1469.
34. Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002;138:325-332.